- Home
- REI vs TLSA Comparison
REI vs TLSA Comparison
Compare REI & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REI | TLSA |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | 9 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.3M | 166.7M |
| IPO Year | 2013 | 2017 |
Fundamental Metrics
Financial Performance| Metric | REI | TLSA |
|---|---|---|
| Price | $1.50 | $1.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.3M | 98.2K |
| Earning Date | 06-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $307,178,072.00 | N/A |
| Revenue This Year | $11.43 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $0.73 |
| 52 Week High | $1.64 | $2.60 |
Technical Indicators
Market Signals| Indicator | REI | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 62.21 | 38.14 |
| Support Level | $0.78 | N/A |
| Resistance Level | $1.64 | $1.61 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 62.49 | 18.06 |
Price Performance
Historical ComparisonAbout REI Ring Energy Inc.
Ring Energy Inc is an independent exploration and production company based in The Woodlands, Texas and is engaged in oil and natural gas development, production, acquisition, and exploration activities currently focused in the Permian Basin of Texas. The drilling operations of the company target the oil and liquid rich producing formations in the Northwest Shelf, the Central Basin Platform and the Delaware Basin all of which are part of the Permian Basin in Texas.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.